Daybue.com
Manufacturing · Idaho, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Lindsay Cir, Ketchum, Idaho, 83340, ...Phone Number
(208) 726-7327Website
www.daybue.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Daybue.com
DAYBUE (trofinetide) is a specialized treatment aimed at addressing specific health conditions. The product is targeted towards caregivers and individuals seeking support for managing these health issues. The company provides resources and information to help users understand and utilize the treatment effectively. Their intended clients include caregivers of individuals affected by the conditions treated by trofinetide.Explore more
Popular SearchesDaybue.comAcadia Pharmaceuticals IncSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Daybue.com your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Daybue.com recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Daybue.com had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Daybue.com
Daybue.com, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Daybue.com launches new products
Funding: Get notified immidiatlly once Daybue.com has new funding data
Check if Daybue.com has recently received funding, and reach out quickly before it becomes old news!
Check out if Daybue.com is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Daybue.com as Masked Content
Find 3 more new buyers
Compare Similar Companies to Daybue.com
Compare insights from companies similar to Daybue.com, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Daybue.com
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Daybue.com is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Daybue.com is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Daybue.com.
Daybue.com Tech Stack
A closer look at the technologies used by Daybue.com
Daybue.com News & Media
Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Med published results from two open-label extension studies, LILAC-1™ and LILAC-2™, which showed that patients treated with DAYBUE™ who completed these studies experienced improvement in Rett symptoms as measured by the Rett Syndrome Behaviour Questionnaire (RSBQ). LILAC-1 was a 40-week, open-label extension study of the 12-week Phase 3 LAVENDER™ trial, evaluating the long-term safety and effAcadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide). “These interim data from the LOTUS sAcadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO. The presentations include outcomes from the DAFFODIL™, a Phase 2/3 open-label study evaluating the safety, tolerability and exploratory efficacy of DAYBUE in girls aged two to four living with Rett syndrome,Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER™ trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE™ in patients with Rett syndrome five to 20 years of age. “The LAVENDER study was designed to measure the effect of DAYBUE treatment on the range of behavioral, communication, and physical Rett syndrome symptoms that significa
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Daybue.com
Sign Up For FreeTo access detailed company insights
DAYBUE (trofinetide) is a specialized treatment aimed at addressing specific health conditions. The product is targeted towards caregivers and individuals seeking support for managing these health issues. The company provides resources and information to help users understand and utilize the treatment effectively. Their intended clients include car... Read More
